Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blackstone Group

Blackstone (NYSE: BX) said on Monday that it had inked an agreement with Japanese Takeda Pharmaceutical Co to buy its consumer healthcare business. Following the completion of the transaction, Takeda wishes to focus primarily on rare diseases and developing drugs to address unmet medical needs.

Blackstone to acquire Takeda Pharmaceutical’s consumer healthcare business

Blackstone Group Inc. BX, +0.91% is buying Takeda Pharmaecutical Co.'s 4502, +0.24% TAK, -0.37% consumer health care business for 242 billion yen ($2.3 billion), the Wall Street Journal reported Monday.

Blackstone to acquire Takeda's consumer health care business for $2.3 billion: WSJ

TAIPEI, Taiwan--(BUSINESS WIRE)--Crest View International financial executives have commented on Takeda as they sell Japanese Consumer Health Unit to Blackstone for $2.3 billion.

Crest View International Comments On Takeda As They Sell Japanese Consumer Health Unit To Blackstone For $2.3 Billion

Takeda Pharmaceutical Co has agreed to sell its Japanese consumer healthcare business to U.S. investment fund Blackstone Group for 242 billion yen ($2.3 billion), Japan's largest drugmaker said on Monday.

Takeda to sell Japanese consumer health unit to Blackstone for $2.3 billion

LEXINGTON, Mass. & OSAKA, Japan--(BUSINESS WIRE)--A new series of public service announcements featuring actress Alex Borstein aims to educate the public about the symptoms of von Willebrand disease.

National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand Disease

Novavax

Global expansion is here for the vaccine that's months away from a regulatory approval.

Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan

GAITHERSBURG, Md. and OSAKA, Japan, Aug.  07, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan

Grifols, S.A.

The results provide more justification for the FDA to grant the substance emergency use authorization.

Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study

AbbVie

Amgen

AbbVie Inc. ABBV, -1.17% , Amgen Inc. AMGN, -0.59% , and Takeda Pharmaceutical Co.

AbbVie, Amgen and Takeda start testing drugs as COVID-19 treatments

SAN FRANCISCO, Aug. 3, 2020 /PRNewswire/ -- Today, members of the COVID R&D Alliance AbbVie, Inc.

Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)-- #TAKEDA--Takeda today presented three abstracts at the 72nd National Hemophilia Foundation’s Bleeding Disorders Conference.

Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020

Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q1 2021 Results - Earnings Call Transcript

Japan's Takeda Pharmaceutical Co on Friday raised its full-year profit forecast as it refocuses on its core prescription drug businesses following its $59 billion takeover of Shire Plc last year.

Takeda Pharma raises profit forecast as it focuses on core drug business

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2020 (quarter ended June 30, 2020). Based on the first quarter performance, the company confirms management guidance, and raises reported operating profit and reported net profit for the full year.

Takeda Announces FY2020 Q1 Results; Confirms Management Guidance & Raises Reported Operating Profit And Reported Net Profit for the Full Year

EXTON, Pa., July 30, 2020 /PRNewswire/ -- The 2020 audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule New Starts in IBD (US) service focuses on a key bellwether of the ulcerative colitis and Crohn's disease markets – the newly initiated patient. Despite the entry of.

Takeda's Entyvio and Janssen's Stelara Share of Inflammatory Bowel Disease Biologic-Naive Patients Continues to Increase as This Patient Group Expands Their Involvement in the Decision-Making Process

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S.

Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Takeda Pharmaceutical Co is looking to cut sales jobs in Japan in its latest restructuring effort, as it overhauls domestic business following its $59 billion purchase of Shire Plc, sources familiar with the company's plans said.

Takeda Pharmaceutical to cut sales jobs in Japan: sources

GlaxoSmithKline

They might not have the most hyped COVID-19 programs. But they do sport the juiciest dividends.

3 Coronavirus Stocks With the Highest Dividend Yields

Novartis

Swedish drugmaker, Novartis (SWX: NOVN), said last week that it will no longer seek European approval for Xiidra (dry-eye drug). According to Takeda Pharmaceutical (TYO: 4502), Novartis decision is expected to result in a £162.50 million of operating loss for the Japanese multinational pharmaceutical company.

Takeda estimates £162.50 million hit to operating loss as Novartis withdraws from European approval for Xiidra

CommScope Hld

PulteGroup

T. Rowe Price Group

ROE is often used to compare the profitability of a company with other firms in the industry ??? the higher, the better.

4 ROE Stocks to Buy as Coronavirus Resurgence Spooks Markets

Takeda Pharmaceutical Co Ltd said on Monday it anticipates an operating loss of about $200 million related to Novartis AG's decision to withdraw a marketing application for the dry-eye drug Xiidra.

Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawal

Blackstone, Bain Capital and Taisho Pharmaceutical are among the final bidders for Takeda Pharmaceutical’s (4502.T) consumer drug business in Japan, a deal that could be worth up to 400 billion yen ($3.7 billion), three people familiar with the deal said.

Exclusive: Blackstone, Taisho Pharma among final bidders for Takeda's Japan OTC unit - sources

Neurocrine Biosciences

During a May 6 earnings conference call, the head of business development and strategy for Neurocrine Biosciences Inc (NASDAQ:NBIX) said the company was looking for other partnerships, similar to those it had recently struck with Xenon Pharmaceuticals Inc.

Neurocrine Adds to Pipeline With $2 Billion Takeda Deal

Emergent BioSolutions

Antibodies of recovered patients can help treat people who are infected with the novel coronavirus.

Who Can Donate Plasma for COVID-19 Patients?

Takeda Pharmaceutical Co Ltd  has agreed to sell a portfolio of over-the-counter and prescription drugs marketed in the Asia Pacific region to South Korea's Celltrion Inc  for $278 million, it said on Thursday

News for Takeda Pharmaceutical Stock (TAK)